IDRA On Other Exchanges
text size: T | T
Back to Snapshot
Company Description

Contact Info

167 Sidney Street

Cambridge, MA 02139

United States

Phone: 617-679-5500

Fax: 617-679-5592

Idera Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates. The company is focused on the development of drug candidates for oncology and rare diseases characterized by small, well-defined patient populations with serious unmet medical needs. Research and Development Programs Toll-like receptor (TLR) Modulation Technology Platform TLRs play a central role in the innate immune system by regulating signaling cascades that stimulate inflammation. Using its chemistry-based platform, the company has designed TLR antagonists and agonists to modulate the activity of targeted TLRs. A TLR antagonist is a compound that inhibits an immune response by downregulating the activity of the targeted TLR. A TLR agonist is a compound that stimulates an immune response by increasing the activity of the targeted TLR. Its TLR antagonist clinical-stage drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. The company also has created compounds that are agonists of TLR3, TLR7, TLR8 or TLR9. Its TLR agonist clinical-stage drug candidates are IMO-2125 and IMO-2055, which are both agonists of TLR9. IMO-8400 Development Program in Genetically Defined Forms of B-cell Lymphoma The company is developing IMO-8400 for the treatment of certain B-cell lymphomas in which the MYD88 L265P oncogenic mutation is present. Oncogenic mutations are changes in the DNA of tumor cells that promote the survival and proliferation of tumor cells. MYD88 is an adaptor protein in the TLR signaling pathway that mediates TLR signaling. Companion Diagnostic for MYD88 L265P-The company has a collaboration with Abbott Molecular, Inc. for the development of a companion diagnostic that could be used to identify patients with the MYD88 L265P oncogenic mutation. Under the agreement, Abbott Molecular is primarily responsible for developing and obtaining regulatory approvals for the companion diagnostic test in accordance with an agreed development plan and regulatory plan and for making the companion diagnostic test commercially available in accordance with an agreed commercialization plan. Application of TLR Agonists in Immuno-Oncology The company’s pipeline of drug candidates includes IMO-2125 and IMO-2055, two TLR9 agonists that might have potential applications as immune therapies for the treatment of cancer. Recent advancements in cancer immunotherapy have included the approval and late-stage development of multiple checkpoint inhibitors, which are therapies that target mechanisms by which tumor cells evade detection by the immune system. The company and its collaborators have previously conducted clinical trials of IMO-2125 and IMO-2055. In these clinical trials, IMO-2055 was evaluated as a monotherapy and in combination with other oncology therapeutics in approximately 300 patients with various types of cancers, and IMO-2125 was evaluated in approximately 95 patients with hepatitis C. To support future potential development in cancer, it has conducted preclinical studies in which its TLR9 agonists have demonstrated anti-tumor activity in combination with multiple checkpoint inhibitors including, ipilimumab, an anti-CTLA4 antibody marketed as Yervoy by Bristol-Myers Squibb Company. In June 2015, the company entered into a strategic clinical research alliance with MD Anderson Cancer Center, or MD Anderson, to advance clinical development of TLR9 agonists in combination with checkpoint inhibitors. Under this alliance, in December 2015, the company initiated a Phase 1/2 clinical trial to assess the safety and efficacy of IMO-2125, administered intra-tumorally in combination with ipilimumab in patients with metastatic melanoma. In this clinical trial, escalating doses of IMO-2125 ranging from 4 mg/kg through 32 mg/kg would be administered intra-tumorally into one of two selected tumor lesions, with a standard dosing regimen of ipilimumab. The primary objective


The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

IDRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDRA.
View Industry Companies

Industry Analysis


Industry Average

Valuation IDRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 397.9x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 274.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact IDERA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at